Disclosed herein are methods for modifying a substrate having a hydrophobic surface. Also disclosed are modified hydrophobic substrates. The modified hydrophobic substrates and methods disclosed herein advantageously improve cell affinity and antithrombogenicity of hydrophobic surfaces.

A medical material uses a nickel-titanium alloy wherein a polyelectrolyte has a reduced thickness while a sufficient amount of an antithrombogenic compound for production of a therapeutic effect is supported. The medical material in which a porous surface is formed on a nickel-titanium alloy to allow infiltration of a polyelectrolyte into the pores, to thereby reduce the thickness of the polyelectrolyte exposed on the surface of the nickel-titanium alloy while allowing supporting of a sufficient amount of an antithrombogenic compound due to contribution of the polyelectrolyte infiltrate.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.

Disclosed herein are methods for modifying a substrate having a hydrophobic surface. Also disclosed are modified hydrophobic substrates. The modified hydrophobic substrates and methods disclosed herein advantageously improve cell affinity and antithrombogenicity of hydrophobic surfaces.

A bioprosthetic valve and a preparation method thereof are provided. The bioprosthetic valve includes a stent and a functional biological tissue material attached to the stent. The functional biological tissue material is a biologicaltissue covalently bonded with an active group and a functional molecule or group. The method improves the anti-thrombosis and anti-calcification functions by covalently modifying the surface of a biological valve using an active group and a functional molecule or group with a substantial degree of grafting. The new bioprosthetic valve does not include aldehyde residues, exhibits excellent biocompatibility, optimal mechanical properties, high stability, and can meet the performance requirements of a biological valve delivered through a catheter.

Disclosed herein are methods for modifying a substrate having a hydrophobic surface. Also disclosed are modified hydrophobic substrates. The modified hydrophobic substrates and methods disclosed herein advantageously improve cell affinity and antithrombogenicity of hydrophobic surfaces.

Medical articles formed from a polyurethane-based resin including an ionically-charged modifier provide enhanced properties. The polyurethane-based resin is a reaction product of ingredients comprising: a diisocyanate; a diol chain extender; a polyglycol; and an anionic modifier incorporated into a backbone, as a side chain, or both of the polyurethane-based resin. Exemplary anionic modifier includes 2,2-bis(hydroxymethyl)butyric acid (BHMBA) and/or bis-1,4-((2-hydroxypropoxy)-2-propoxy)-butane sulfonate sodium salt (SULFADIOL®-7Q). Medical articles herein either have inherent antimicrobial and/or anti-fouling characteristics or can easily bond cationic active agents to provide desirable material properties, including antimicrobial, anti-fouling, and/or radiopacity.

Provided herein is a prosthetic heart valve device including a biocompatible and biodegradable metal frame comprising a proximal end, a distal end, and a sidewall therebetween, the sidewall having a plurality of openings therethrough. The device further includes a biocompatible and biodegradable polymeric heart valve having an annular portion attached at least one contact point to the proximal end of the frame and at least one leaflet attached to and extending distally from the annular portion.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.

An antithrombogenic metallic material includes a metallic material whose surface is coated with a coating material, the coating material containing: a phosphonic acid derivative or a catechol derivative; a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; the polymer being covalently bound to the phosphonic acid derivative or the catechol derivative, the phosphonic acid derivative or the catechol derivative being bound to the metallic material through a phosphonic acid group or a catechol group thereof, wherein the abundance ratio of nitrogen atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface is 4.0 to 13.0 atomic percent.